Kidney Week 2024 is the annual meeting of the American Society of Nephrology (ASN). The scientific program included early programs, plenary sessions, late-breaking clinical trials, symposia, and posters.
Travere at ASN Kidney Week
Travere Therapeutics attended the American Society of Nephrology annual meeting in San Diego, CA.
Program
Sparsentan (SPAR) in Pediatric Patients With Rare Proteinuric Kidney Disease: Preliminary Findings From the EPPIK Study
Speakers: Howard Trachtman, Rosanna Coppo, Nuhira Ahmed Masthan Ahmed, Kenneth V. Lieberman, Alex Mercer, Michelle N. Rheault, Moin A. Saleem, Radko Komers
Contact your MSL Travere
Our Medical Science Liaisons (MSLs) are available to answer questions and provide support on Travere products.
Contact an MSLHealth-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan
Speakers: Isabelle Ayoub, Mark E. Bensink, Xiaolei Zhou, Jinyi Wang, Wu Gong, Priscila Preciado, Radko Komers, Jula K. Inrig, Michelle N. Rheault, Howard Trachtman
Outcomes of the DUPLEX Trial in Patients With Genetic Focal Segmental Glomerulosclerosis (gFSGS)
Speakers: Jennifer Yee, Wu Gong, Jula Inrig, Michelle N. Rheault, Radko Komers, Howard Trachtman
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors in Adults With IgA Nephropathy in the Ongoing Phase 2 SPARTACUS Trial
Speakers: Isabelle Ayoub, Sydney Tang, Laura Kooienga, Priscila Preciado, David S. Lee, Stephanie Moody, Brad H. Rovin
Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Patients With IgA Nephrology (IgAN) in the PROTECT Open-Label Extension (OLE)
Speakers: Laura Kooienga, Robert Malecki, Priscila Preciado, Heeral Nandola, Alex Mercer on behalf of the DUPRO Steering Committee and PROTECT investigators
Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan With Irbesartan for Immunoglobulin A Nephropathy
Speakers: Shikha Wadhwani, Mark E. Bensink, John D. Peipert, Isabelle Ayoub, Priscila Preciado, Diana Garbinsky, Jinyi Wang, Jimin Choi, Lee Bennett, Wu Gong, Jula K. Inrig, Radko Komers
Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT
Speakers: Hiddo JL. Heerspink, Vladimir Tesar, Radko Komers, Bruce M. Hendry, Priscila Preciado, Edward Murphy, Brad H. Rovin on behalf of the DUPRO Steering Committee and PROTECT investigators
Sparsentan in Combination With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN): A Case Series
Speakers: Prasanth Ravipati, Gates Colbert, Sarah J. Evans, Agnes Pelts Block, Christopher Gisler, Renuka Sothinathan
Sparsentan in Patients With Prior or Concurrent Immunosuppressive Treatment (IST) for IgA Nephropathy (IgAN): A Case Series
Speakers: Luis E. Vélez, Reva Siva, Agnes Pelts Block, Christopher Gisler, Pablo Garcia
PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g/g
Speakers: Laura Kooienga, Hernán Trimarchi, Jürgen Floege, Priscila Preciado, Edward Murphy, Jai Radhakrishnan
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy (IgAN): Interim Analysis of the SPARTAN Trial
Speakers: Chee Kay Cheung, Stephanie Moody, Neeraj Dhaun, Siân Griffin, Alexandra Howson, Radko Komers, Alex Mercer, Matthew Sayer, Smeeta Sinha, Lisa Willcocks, Jonathan Barratt
MA-DS-24-0017 | August 2024